GE HealthCare Technologies (NASDAQ:GEHC) Given New $73.00 Price Target at UBS Group

GE HealthCare Technologies (NASDAQ:GEHC) had its price target boosted by UBS Group from $67.00 to $73.00 in a research report released on Friday,Benzinga reports. The firm currently has a neutral rating on the stock.

Other equities research analysts have also issued research reports about the company. Weiss Ratings lowered GE HealthCare Technologies from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday, May 15th. Hovde Group started coverage on GE HealthCare Technologies in a report on Friday, July 17th. They issued a “market perform” rating and a $14.00 target price for the company. HSBC dropped their price target on GE HealthCare Technologies from $100.00 to $90.00 in a research note on Thursday, April 30th. The Goldman Sachs Group restated a “neutral” rating on shares of GE HealthCare Technologies in a report on Monday, June 8th. Finally, Piper Sandler reaffirmed a “buy” rating on shares of GE HealthCare Technologies in a research report on Wednesday. Ten investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, GE HealthCare Technologies presently has a consensus rating of “Hold” and an average target price of $77.73.

GE HealthCare Technologies Price Performance

GEHC stock opened at $68.02 on Friday. The firm has a market cap of $30.94 billion, a price-to-earnings ratio of 15.60, a PEG ratio of 1.90 and a beta of 0.72. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 0.92. GE HealthCare Technologies has a 12-month low of $58.75 and a 12-month high of $89.77. The company’s fifty day simple moving average is $64.02 and its 200 day simple moving average is $70.55.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its quarterly earnings results on Wednesday, July 29th. The company reported $1.13 EPS for the quarter, beating analysts’ consensus estimates of $1.04 by $0.09. GE HealthCare Technologies had a net margin of 9.33% and a return on equity of 20.12%. The business had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.26 billion. During the same quarter in the prior year, the firm posted $1.06 earnings per share. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. On average, analysts expect that GE HealthCare Technologies will post 4.89 earnings per share for the current year.

GE HealthCare Technologies Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Friday, July 24th will be given a $0.035 dividend. This represents a $0.14 dividend on an annualized basis and a yield of 0.2%. The ex-dividend date of this dividend is Friday, July 24th. GE HealthCare Technologies’s payout ratio is presently 3.21%.

Insider Buying and Selling

In other news, Director Watkin Phoebe L. Yang purchased 1,000 shares of the company’s stock in a transaction that occurred on Friday, May 8th. The shares were acquired at an average cost of $63.01 per share, with a total value of $63,010.00. Following the purchase, the director owned 13,702 shares in the company, valued at $863,363.02. This represents a 7.87% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Kevin Lobo acquired 10,000 shares of GE HealthCare Technologies stock in a transaction on Friday, May 22nd. The stock was purchased at an average cost of $64.18 per share, with a total value of $641,800.00. Following the purchase, the director directly owned 14,363 shares of the company’s stock, valued at approximately $921,817.34. This trade represents a 229.20% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have bought 12,618 shares of company stock valued at $805,175. 0.36% of the stock is owned by company insiders.

Hedge Funds Weigh In On GE HealthCare Technologies

A number of large investors have recently modified their holdings of GEHC. Auto Owners Insurance Co increased its stake in GE HealthCare Technologies by 9,525.4% during the 4th quarter. Auto Owners Insurance Co now owns 33,982,610 shares of the company’s stock valued at $278,725,000 after purchasing an additional 33,629,559 shares in the last quarter. Norges Bank acquired a new position in GE HealthCare Technologies during the fourth quarter worth $596,024,000. Barrow Hanley Mewhinney & Strauss LLC bought a new position in shares of GE HealthCare Technologies in the fourth quarter valued at $533,655,000. Cynosure Group LLC lifted its stake in shares of GE HealthCare Technologies by 21,045.4% in the fourth quarter. Cynosure Group LLC now owns 4,365,462 shares of the company’s stock valued at $358,055,000 after buying an additional 4,344,817 shares in the last quarter. Finally, Boston Partners acquired a new position in shares of GE HealthCare Technologies during the third quarter valued at about $287,627,000. 82.06% of the stock is currently owned by institutional investors.

Key Headlines Impacting GE HealthCare Technologies

Here are the key news stories impacting GE HealthCare Technologies this week:

• Positive Sentiment: Better-than-expected earnings and raised guidance: GE HealthCare reported adjusted earnings of $1.13 per share, exceeding the $1.04 consensus estimate, while revenue of $5.30 billion also topped expectations. Revenue increased 5.8% year over year, and management raised its full-year EPS outlook. GE HealthCare Q2 2026 Earnings Call Summary
• Positive Sentiment: Record backlog and solid demand: Strong orders growth and a record backlog support expectations for future revenue growth and helped reinforce the bullish case for GEHC. Analysts highlighted the backlog as evidence of durable demand for the company’s medical technology and imaging products. GE HealthCare Q2 Earnings Call Highlights
• Positive Sentiment: Analyst support increased: Wells Fargo raised its price target from $75 to $85 and maintained an “overweight” rating. BTIG Research also forecast substantial appreciation, providing additional support for the shares. Wells Fargo Raises GE HealthCare Price Target
• Neutral Sentiment: Execution remains a key issue: Some analysis described demand as strong but execution as weaker, suggesting investors will watch margins, delivery performance and the company’s ability to convert its backlog into sustained earnings growth. GE HealthCare Strong Demand, Weak Execution
• Negative Sentiment: Shareholder investigations create legal uncertainty: Multiple law firms announced or continued investigations into possible securities-law violations and solicited investors who lost money. These announcements do not establish wrongdoing, but they may weigh on sentiment and raise potential litigation concerns. GEHC Securities Fraud Investigation

About GE HealthCare Technologies

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.